Dishman Pharmaceuticals & Chemicals has received an approval to raise up to Rs 200 crore by way of issue of shares to Qualified Institutional Investors (QIP), subject to approval of members. The board of directors at its meeting held on August 13, 2014 has approved for the same.
Dishman Pharmaceuticals is engaged in the manufacturing of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals.
